What CHMP did on its summer holiday: indication extensions
This article was originally published in Scrip
Following the CHMP's annual August holiday, the September meeting of the committee saw a glut of positive recommendations on extensions of therapeutic indications.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.